Heparin calcium

肝素钙

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameHeparin calcium
Drug Alias Name钙合肝素Calcium HeparinHeparin Sodyum低分子肝素钙Heparinkalcium +[11] 
ClassificationSmall molecules > Carbohydrate
Mechanisms of ActionAntithrombin-III activators
TargetsAntithrombin-III
Therapy Area/IndicationsBlood Coagulation DisordersThrombophlebitisVenous Thromboembolism +[10] 
Global Approved IndicationsBlood Coagulation DisordersVenous Thromboembolism
Approved Indications in ChinaBlood Coagulation DisordersVenous Thromboembolism
Original Approved Country/TerritoryMainland China
Original Approved Date2000/12/07
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofi Synthelabo Hk Ltd
Inactive CompaniesNational Institutes Of Health Clinical Center (Cc)National Heart, Lung, And Blood Institute (Nhlbi)
Active IndicationsBlood Coagulation DisordersVenous Thromboembolism
Inactive IndicationsThrombophlebitisEmbolismMyocardial Infarction +[8] 

Other Information

ATC CodeB01AB01C05BA03S01XA14
Related LinksWikipediaDrugBankKEGG